Rheumatoid arthritis discovery may lead to novel inflammation blockers
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
List view / Grid view
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
Removing stress hormones in mouse models restored proper function to immune cells and epithelial cells, pointing to new Crohn's treatments.
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
Scientists targeted a mouse's own cells using a synthetic molecule called EEZE, presenting a novel way to treat pneumonia.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
27 October 2021 | By Takara Bio
Watch this free one-hour session to discover how refined cell atlases can provide comprehensive roadmaps for health and disease.
This whitepaper overviews phenotypic and functional characterisation of CAR-T cells with advanced flow cytometry and live-cell analysis.
The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.
Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
A new study has suggested that mucosal vaccines may reduce transmission of airborne viruses such as COVID-19 more than injectable vaccines.